DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Authors: Dr Anes Yang, Clinical Researcher, Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia; Dr Monisha Gupta, Senior Staff Specialist, Department of Dermatology, Liverpool Hospital, Sydney, NSW, Australia. DermNet NZ Medical Editor: Dr Delwyn Dyall-Smith, Dermatologist, Wagga Wagga, NSW, Australia; DermNet NZ Editor in Chief: Adjunct Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. September 2018.
Chloroquine is a synthetic antimalarial medication that was first developed in 1934. In addition to its antimalarial effects, chloroquine has been used extensively in rheumatology and dermatology since the 1950s.
Despite its early successes, the use of chloroquine has mostly been superseded by hydroxychloroquine, a safer hydroxylated analogue, and its availability is now limited.
Chloroquine has immunomodulatory and anti-inflammatory effects and may also have a photoprotective effect .
Chloroquine and hydroxychloroquine have the same indications and usage, although the dosage regimens are different. Head-to-head comparisons suggest similar responses with equivalent doses, but greater retinal toxicity with chloroquine .
In dermatology, antimalarial drugs, such as chloroquine, are regarded as appropriate treatments for:
Antimalarial drugs are sometimes also used to treat other inflammatory skin diseases .
Children aged under 6 years of age should not be given chloroquine due to the risk of overdose and acute toxicity.
The chloroquine dose should be reduced in patients with renal disease, as up to 70% of chloroquine is excreted unchanged in the urine. Chloroquine itself can cause reduced kidney function of up to 10% of patients, especially in those over 60 years of age. Renal impairment results in higher blood levels of chloroquine and therefore an increased toxicity risk.
Chloroquine should be used with caution in patients with known porphyria cutanea tarda. Chloroquine can be used to treat porphyria cutanea tarda, but in a very low dose (125 mg twice weekly) as a dosage of 250 mg/day can trigger a porphyria crisis, which can be fatal.
Chloroquine is contraindicated where there is a known hypersensitivity to 4-aminoquinoline compounds.
Chloroquine crosses the placenta and is also found in low levels in breast milk, so pregnancy and lactation are often listed as contraindications to its use (see DermNet NZ’s pages on Safety of medicines taken during pregnancy and on Lactation and the skin). However, effects on the fetus and baby have been rarely reported and chloroquine has been continued during pregnancy and lactation when required for malaria.
Pre-existing retinopathy (damage to the retina) and other eye problems, such as macular degeneration (blurred vision in the centre of the eye) and cataracts, make monitoring more difficult, and so can also be relative contraindications.
Although chloroquine can occasionally trigger a flare of psoriasis, this is not an absolute contraindication, and the use of the drug should be decided in individual cases.
Chloroquine has similar pharmacokinetics to hydroxychloroquine. After identical doses, the tissue levels of chloroquine are 2.5 times those seen with hydroxychloroquine. Chloroquine is rapidly and almost completely absorbed from the bowel following oral administration.
Peak plasma concentrations of chloroquine are reached within 4–12 hours, but it takes 4–6 weeks for plasma concentrations to stabilise; therefore, it will take 2–3 months to see a therapeutic effect. Up to 70% of chloroquine is excreted unchanged through the kidneys and up to 40% is metabolised in the liver into an active metabolite.
Chloroquine binds to plasma proteins that are deposited in tissues, such as the liver, spleen, kidney, and lung. Chloroquine has a particularly high affinity for melanin-containing cells and hence there are very high levels of chloroquine in the skin (mainly, the epidermis) and retina. Chloroquine has a long half-life, which can vary between 74 hours and 50 days, depending on the cumulative dose.
The drug can remain in the skin for 6–7 months after the cessation of therapy.
Chloroquine phosphate is dispensed as a 250 mg tablet, which is equivalent to 155 mg chloroquine base.
Long-term chloroquine use should aim for <2.3 mg/kg/day based on the patient's actual body weight. Given the tablet size, this usually means it needs to be used intermittently; that is, several times per week instead of daily. Previously, the maximum daily dose was calculated on the patient's ideal body weight, and cumulative dose was recommended to be less than 460 g. These guidelines have been revised.
In porphyria cutanea tarda, the dose should not exceed 125 mg twice weekly.
Chloroquine is not marketed in Australia, where it is only available through the Therapeutic Goods Administration's Special Access Scheme. It is no longer approved for use in New Zealand, but may be available under Section 29 (see Medsafe's information on unapproved medications).
No dosage adjustment of chloroquine for hepatic impairment is provided in the manufacturer’s labelling.
The following guidance is given for chloroquine dosing in cases of renal impairment:
The two main ocular effects of chloroquine are reversible corneal deposits and irreversible retinal toxicity.
Corneal deposits occur rapidly in 90% of patients on chloroquine. They are usually asymptomatic; however, patients can experience transient halos and heightened light sensitivity.
Finding corneal deposits on examination does not mean chloroquine should be stopped.
Deposits are dose related, occurring 1–1.5 months after therapy is initiated and resolve after the discontinuation of chloroquine.
Irreversible retinal toxicity, causing bilateral bull’s eye retinopathy from chloroquine has been recognised for many years. This is a late-stage finding and should not be seen if regular monitoring is conducted. The high affinity of chloroquine for melanin-containing cells, such as those found in the retinal pigment epithelium, is hypothesised to be the cause.
Patients with antimalarial-induced retinal toxicity may not have any visual symptoms initially and will only develop clinical symptoms in the late stages.
The cessation of the drug when definite signs of early retinopathy are found is important, as chances of vision loss will typically decrease. Chloroquine should only be ceased if there are definite signs of retinal toxicity; possible toxicity should be reassessed after several months with continued drug use. Continued use of chloroquine after a finding of definite retinopathy results in irreversible visual damage, including effects on visual acuity, peripheral vision, and night vision.
This retinopathy does not reverse, even with the cessation of the chloroquine, and there is no treatment. The risk of retinal toxicity is highest with chloroquine compared to other antimalarials .
In 2016, with new scientific data, the American Academy of Ophthalmology revised their screening recommendations for patients on chloroquine for longer than 1 year . The two most important risk factors for retinopathy are the duration of chloroquine treatment and a daily dose of chloroquine >2.3 mg/kg of the patient's actual body weight.
Monitoring is of particular importance in patients over 60 years of age and in those with renal impairment.
Every patient planning to take chloroquine for at least 12 months should undergo a baseline ophthalmic examination within 6 months of commencing chloroquine and then annually. A fundus examination alone is not sufficient screening; the examination should involve automated visual fields testing and spectral-domain optical coherence tomography .
Chloroquine can cause:
Chloroquine can cause nausea, vomiting and diarrhoea; these side effects are often transient or resolve with dose reduction. Symptoms can be minimised by taking the medication with food.
Haemolytic anaemia and reduced blood cell counts occur very rarely at recommended doses of chloroquine but may occasionally occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Neuromyopathy (diseases of the nerves and muscle tissues), myalgia, and fatigue have been reported with chloroquine use. Care should therefore be taken in patients with myasthenia gravis and dermatomyositis.
The following medications should be reviewed when used concomitantly with chloroquine:
Smoking has been reported to inhibit the cytochrome P450 enzyme system, decreasing the efficacy of chloroquine .
See the DermNet NZ bookstore.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.